Streetbeat News

NGNE

Neurogene Inc.

https://www.neurogene.com

Industry

Biotechnology

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.

Open

20.90

Mkt cap

224M

Volume

1.2M

High

20.99

P/E Ratio

-4.71

52-wk high

74.49

Low

17.01

Div yield

N/A

52-wk low

12.49

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Neurogene Inc. (NASDAQ:NGNE) stockholders. Investors are encouraged to inquire about the securities investigation.

Portfolio Pulse from

November 22, 2024 | 3:15 pm

Pomerantz Law Firm is investigating claims on behalf of investors of Neurogene Inc. (NASDAQ:NGNE). Investors are encouraged to contact the firm for more information.

Portfolio Pulse from

November 22, 2024 | 3:15 pm

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors in Neurogene Inc. (NASDAQ:NGNE). Investors are encouraged to learn more about the investigation.

Portfolio Pulse from

November 21, 2024 | 3:15 pm

Levi & Korsinsky has initiated an investigation into Neurogene Inc. (NASDAQ:NGNE) for potential securities fraud related to their recent press release on clinical trial data for NGN-401 gene therapy.

Portfolio Pulse from

November 21, 2024 | 12:45 pm

Pomerantz Law Firm is investigating claims on behalf of investors of Neurogene Inc. (NASDAQ:NGNE). Investors are encouraged to contact the firm for more information.

Portfolio Pulse from

November 20, 2024 | 6:00 pm

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Neurogene Inc. shareholders. Investors are encouraged to contact the firm for more information.

Portfolio Pulse from

November 20, 2024 | 3:15 pm

Levi & Korsinsky has initiated an investigation into Neurogene Inc. for potential securities fraud related to its recent press release on clinical trial data for NGN-401 gene therapy.

Portfolio Pulse from

November 20, 2024 | 12:45 pm

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors in Neurogene Inc. (NASDAQ:NGNE). Investors are encouraged to participate in the investigation by visiting the firm's website for more information.

Portfolio Pulse from

November 19, 2024 | 3:15 pm

Levi & Korsinsky has initiated an investigation into Neurogene Inc. for potential violations of federal securities laws. This follows Neurogene's recent press release about interim clinical data from its NGN-401 gene therapy trial.

Portfolio Pulse from

November 19, 2024 | 12:45 pm

Pomerantz LLP is investigating claims on behalf of investors of Neurogene Inc. (NASDAQ: NGNE). Investors are encouraged to contact the law firm for more information.

Portfolio Pulse from

November 19, 2024 | 12:45 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.